Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > MBX Q4 Earnings
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(116)
•••
Comment by wizzdumbon Dec 21, 2023 10:08am
154 Views
Post# 35795577

RE:RE:MBX Q4 Earnings

RE:RE:MBX Q4 Earnings

They saved the good stuff for Q1 2024, 2023 was confluence of negative factors like delayed QAPs sales and no VTM, whereas 2024 will be the opposite. 

Closest thing to forward guidance you will get is KRC report which has FY2024 at about $32M including the Kinlytic royalty payments, which is 75% growth YOY. Personally I think this is a conservative estimate. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities